Floatz logo

FILGRASTIM

Colorectal Neoplasm

Eli Lilly and Companyprotein_peptidePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Colorectal Neoplasm cohort.

Asset / SponsorPhaseRating
Capecitabine
Rutgers, The State University of New Jersey
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Nottingham University Hospitals NHS Trust
Phase 4BBB
Nivolumab
Bristol-Myers Squibb
Phase 3BB
IRON(II) SULPHATE (1:1), HEPTAHYDRATE
Nottingham University Hospitals NHS Trust
Phase 4BB
FERRIC CATION
Nottingham University Hospitals NHS Trust
Phase 4BB

View all 25 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →